| P50 | author | Fares Ayoub | Q38641831 |
| P2093 | author name string | Jorge Lascano | |
| | Giuseppe Morelli | |
| | Cesar Trillo-Alvarez | |
| P2860 | cites work | Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B. | Q46869308 |
| | Clinical manifestations of cystic fibrosis among patients with diagnosis in adulthood | Q47911415 |
| | Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry. | Q50664409 |
| | Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity. | Q50717522 |
| | Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study | Q51541188 |
| | Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. | Q53635363 |
| | Analysis of risk factors for the development of liver disease associated with cystic fibrosis | Q72274632 |
| | Cystic fibrosis with extensive fat replacement of the liver | Q72875038 |
| | Ultrasonography of alcoholic liver disease with histological correlation | Q72910094 |
| | Natural history of liver disease in cystic fibrosis | Q73114499 |
| | Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group | Q77958537 |
| | Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome | Q78560745 |
| | APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C | Q79852758 |
| | Liver disease in cystic fibrosis | Q81365513 |
| | Hepatobiliary abnormalities and disease in cystic fibrosis: epidemiology and outcomes through adulthood | Q84068608 |
| | Liver disease in cystic fibrosis | Q87512588 |
| | Nonalcoholic fatty liver disease: a systematic review | Q28263139 |
| | Cirrhosis and other liver disease in cystic fibrosis | Q28660820 |
| | A single centre experience of liver disease in adults with cystic fibrosis 1995-2006. | Q33377573 |
| | Endpoints and clinical trial design for nonalcoholic steatohepatitis | Q33583798 |
| | Liver cirrhosis in cystic fibrosis--therapeutic implications and long term follow up. | Q33623427 |
| | Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society | Q34351928 |
| | AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection | Q34454310 |
| | Cholangiocyte biology and cystic fibrosis liver disease | Q34464126 |
| | Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. | Q36232237 |
| | Imaging the Abdominal Manifestations of Cystic Fibrosis | Q37637314 |
| | Cystic fibrosis-associated liver disease | Q37801087 |
| | Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease | Q37887181 |
| | US cannot be used to predict the presence or severity of hepatic steatosis in severely obese adolescents | Q37959440 |
| | Fatty acid composition of serum phospholipids in cystic fibrosis (CF) patients with or without CF related liver disease | Q39825765 |
| | Tumor necrosis factor stimulates hepatic lipid synthesis and secretion | Q41305482 |
| | Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis | Q41714520 |
| | A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease | Q42545724 |
| | Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. | Q42923153 |
| | Fatty infiltration of the liver: quantification with phase-contrast MR imaging at 1.5 T vs biopsy | Q44104530 |
| | Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease | Q44290461 |
| | Liver function and morphology during long-term fatty acid supplementation in cystic fibrosis. | Q44339733 |
| | Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis | Q46203257 |
| | Evolution of pancreatic function during the first year in infants with cystic fibrosis | Q46418227 |
| | ASAT/ALAT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis | Q46495880 |
| P433 | issue | 1 | |
| P921 | main subject | metabolic dysfunction–associated steatotic liver disease | Q1546498 |
| | cystic fibrosis | Q178194 |
| | steatosis | Q1365091 |
| | non-alcoholic fatty liver | Q66299798 |
| P304 | page(s) | 34-40 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | World Journal of Hepatology | Q27723328 |
| P1476 | title | Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease | |
| P478 | volume | 10 | |